Schellong, Sebastian

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine

Venous Thromboembolism Diagnosis and ManagementAtrial Fibrillation Management and Outcomes

Cited by 983

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation

Venous Thromboembolism Diagnosis and ManagementAtrial Fibrillation Management and Outcomes

Cited by 923

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 879

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 754

Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial

Koehler, F., Koehler, K., Deckwart, O., Prescher, S., Wegscheider, K., Kirwan, B.-A., Winkler, S., Vettorazzi, E., Bruch, L., Oeff, M., et al. (2018) · The Lancet

Heart Failure Treatment and ManagementTelemedicine and Telehealth Implementation

Cited by 739

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A. (2008) · Blood

Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

Cited by 342

Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., & Schellong, S. (2007) · Circulation

Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

Cited by 337

Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER ® , RE-COVER™ II, and RE-MEDY™

Goldhaber, S. Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., & Schulman, S. (2016) · Vascular Medicine

Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

Cited by 89